Summary: In a post hoc analysis of three clinical trials spanning the glucose tolerance spectrum, fasting and 1-hour circulating Gremlin…
Browsing: Type 2 Diabetes
Landmark trials and recent evidence on type 2 diabetes management, glucose-lowering therapy, and outcomes.
A secondary cost-consequence and budget impact analysis of the TELE-DD trial found a nurse-led telephone program for nonadherent Type 2 diabetics with comorbid depression became cheaper per glycaemically controlled patient by 12-18 months. PICO summary and expert commentary.
A 2-centre factorial RCT in 273 Chinese adults with type 2 diabetes found the Dnurse app did not significantly improve HbA1c attainment, though systolic blood pressure fell in the app arms. PICO summary and expert commentary.
A phase 3 open-label trial in 440 Chinese adults found the dulaglutide biosimilar LY05008 met its equivalence margin for HbA1c reduction against reference dulaglutide. PICO summary and expert commentary.
A small mechanistic RCT (n=34) found ertugliflozin did not increase proximal tubular natriuresis (the primary outcome) but did reduce fluid volume and blood pressure by week 12. PICO summary and expert commentary.
A small open-label Spanish RCT found a digital education program added to GLP-1 therapy produced greater HbA1c, weight, and adherence gains than usual care over six months. PICO summary and expert commentary.
A small open-label randomised trial comparing dapagliflozin with insulin glargine as a fourth agent for glycaemic variability in type 2 diabetes inadequately controlled on triple therapy. PICO summary and expert commentary.
In 22,220 older US adults, daily vitamin D did not significantly reduce incident type 2 diabetes, though a pooled meta-analysis hinted at a modest benefit. PICO summary and expert commentary.
A three-arm randomized trial in Texans with uncontrolled type 2 diabetes found that all three self-paced virtual and technology-based self-management programs significantly reduced A1c, with no in-person comparator. PICO summary and expert commentary.
A Hong Kong cluster RCT found point-of-care capillary HbA1c screening doubled uptake and detected more type 2 diabetes than venous HbA1c testing in at-risk primary care patients. PICO summary and expert commentary.